|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 471/04 | (2006.01) |
| A61P 35/00 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 37/00 | (2018.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61K 31/4745 | (2013.01) | ||
| A61K 31/437 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| C07D 471/04 | (2013.01) |
| (11) | Number of the document | 3753938 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20169634.1 |
| Date of filing the European patent application | 2018-02-16 | |
| (97) | Date of publication of the European application | 2020-12-23 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-20 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201762460677 P | 2017-02-17 | US | |
| 201762490881 P | 2017-04-27 | US | |
| 201762573991 P | 2017-10-18 | US |
| (72) |
GLICK, Gary , US
GHOSH, Shomir , US
ROUSH, William R. , US
OLHAVA, Edward James , US
O'MALLEY, Daniel , US
|
| (73) |
Innate Tumor Immunity, Inc. ,
Route 206 and Province Line Road, Princeton, New Jersey 08543,
US
|
| (54) | SUBSTUTUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS |
| SUBSTUTUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS |